Your browser is no longer supported. Please, upgrade your browser.
ACER [NASD]
Acer Therapeutics Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own0.50% Shs Outstand14.31M Perf Week-5.78%
Market Cap31.50M Forward P/E- EPS next Y-1.07 Insider Trans15.91% Shs Float12.11M Perf Month-5.36%
Income-17.20M PEG- EPS next Q-0.08 Inst Own29.40% Short Float1.89% Perf Quarter-12.40%
Sales0.90M P/S35.00 EPS this Y29.40% Inst Trans0.02% Short Ratio3.53 Perf Half Y-15.20%
Book/sh0.15 P/B14.13 EPS next Y-46.60% ROA-52.20% Target Price11.00 Perf Year-42.23%
Cash/sh0.96 P/C2.22 EPS next 5Y- ROE-305.10% 52W Range1.68 - 5.39 Perf YTD-7.02%
Dividend- P/FCF- EPS past 5Y37.30% ROI- 52W High-60.67% Beta1.16
Dividend %- Quick Ratio0.80 Sales past 5Y- Gross Margin- 52W Low26.19% ATR0.15
Employees20 Current Ratio0.80 Sales Q/Q- Oper. Margin- RSI (14)43.00 Volatility6.64% 6.93%
OptionableYes Debt/Eq0.00 EPS Q/Q55.60% Profit Margin- Rel Volume0.35 Prev Close2.20
ShortableYes LT Debt/Eq0.00 EarningsNov 30 AMC Payout- Avg Volume64.74K Price2.12
Recom2.00 SMA20-6.67% SMA50-4.74% SMA200-16.74% Volume22,981 Change-3.64%
Jun-26-19Reiterated H.C. Wainwright Buy $55 → $10
Jun-25-19Downgrade William Blair Outperform → Mkt Perform
Jun-25-19Downgrade Raymond James Outperform → Mkt Perform
May-23-19Initiated Wedbush Outperform
Feb-15-19Resumed Raymond James Outperform $40
Dec-20-18Initiated Needham Buy $48
Feb-26-18Initiated ROTH Capital Buy
Dec-20-17Initiated H.C. Wainwright Buy $50
Jan-13-22 09:40AM  
Jan-07-22 04:29AM  
Dec-22-21 08:30AM  
Dec-09-21 08:30AM  
Nov-22-21 03:43AM  
Nov-19-21 05:00PM  
Oct-26-21 08:30AM  
Oct-09-21 08:09AM  
Oct-07-21 10:58AM  
08:44AM  
08:30AM  
Oct-06-21 12:08PM  
08:30AM  
07:21AM  
07:12AM  
Oct-01-21 08:04PM  
Sep-06-21 08:00AM  
Aug-30-21 08:30AM  
Aug-10-21 06:45PM  
04:05PM  
Aug-09-21 08:30AM  
01:30AM  
Jul-08-21 11:20AM  
Jun-23-21 09:35AM  
Jun-22-21 06:46AM  
Jun-13-21 02:11PM  
Jun-10-21 08:30AM  
Jun-09-21 12:00PM  
May-25-21 08:30AM  
May-17-21 04:01PM  
Mar-30-21 01:23AM  
Mar-29-21 08:30AM  
Mar-25-21 04:05PM  
Mar-22-21 08:30AM  
Mar-15-21 08:37AM  
Mar-01-21 04:05PM  
08:30AM  
Feb-11-21 08:30AM  
Jan-25-21 08:35AM  
Dec-22-20 08:30AM  
Dec-17-20 08:30AM  
Nov-10-20 04:05PM  
Oct-15-20 09:30AM  
Oct-02-20 02:37PM  
Oct-01-20 07:04AM  
Sep-28-20 03:30PM  
Aug-31-20 05:00PM  
Aug-25-20 09:00AM  
Aug-13-20 04:01PM  
Aug-05-20 09:00AM  
Jul-28-20 11:09AM  
Jul-27-20 07:29PM  
Jul-09-20 03:55PM  
03:43PM  
Jul-08-20 04:01PM  
Jun-24-20 01:53PM  
May-29-20 12:44PM  
May-21-20 08:30AM  
May-14-20 04:01PM  
May-11-20 04:05PM  
Apr-30-20 04:01PM  
Mar-18-20 04:05PM  
04:05PM  
Feb-26-20 03:00AM  
Feb-25-20 03:00AM  
Feb-24-20 04:05PM  
Jan-28-20 06:16PM  
Jan-05-20 07:00AM  
Dec-23-19 03:59PM  
Dec-17-19 07:56AM  
Dec-16-19 04:05PM  
Dec-05-19 12:50PM  
Nov-13-19 04:05PM  
Oct-28-19 04:01PM  
Oct-07-19 07:05AM  
Sep-11-19 08:00PM  
Aug-30-19 03:00PM  
02:30PM  
01:02PM  
10:04AM  
08:59AM  
Aug-29-19 10:00PM  
03:18PM  
12:27PM  
12:23PM  
Aug-28-19 09:34PM  
06:46PM  
01:00PM  
10:02AM  
Aug-27-19 10:00AM  
08:30AM  
06:35AM  
Aug-26-19 08:00PM  
07:33PM  
06:14PM  
Aug-25-19 10:28AM  
Aug-24-19 06:55AM  
Aug-23-19 08:00PM  
08:00PM  
06:06PM  
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 1991 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASELAGE STEVEDirectorDec 10Buy2.047,98416,28773,905Dec 13 04:02 PM
ASELAGE STEVEDirectorDec 09Buy2.152,0164,33465,921Dec 13 04:02 PM